Research Publications by Dr Nguyen
Nguyen TG. (2022) The Therapeutic Implications of Activated Immune Responses Via the Enigmatic Immunoglobulin D. International Reviews of Immunology; 41(2):107-122.
* This is the first review of published and corroborating evidence of the therapeutic effects and mode of actions of anti-IgD antibody in animal models of autoimmune and allergic conditions.
Nguyen TG. (2020) Harnessing Newton’s 3rd Law Paradigm to Treat Autoimmune Diseases and Chronic Inflammations. Inflammation Research; 69(9):813-824.
* This is the first review to outline the rationale and supporting evidence of activating immune responses to trigger the body’s inbuilt regulatory feedback immune tolerance mechanism and anti-inflammatory responses to alleviate autoimmune and chronic inflammations.
Nguyen TG. (2018) Immune-modulation via IgD B-cell Receptor Suppresses Allergic Skin Inflammation in Experimental Contact Hypersensitivity Models Despite A Th2-favoured Humoral Response. Immunology Letters; 203:29-39.
* The first study to demonstrate the B-cell depletion and immune-modulating effects by anti-IgD mAb treatment in alleviating allergic skin inflammations in CHS animal models and superior efficacy over anti-CD20 mAb treatment.
Nguyen TG & Morris JM. (2014) Signals from Activation of B-cell Receptor with anti-IgD Can Override the Stimulatory Effects of Excess BAFF on Mature B cells In Vivo. Immunology Letters; 161(1):157-162.
* The first study to highlight the potential therapeutic application of anti-IgD mAb treatment to overcome the survival and growth effects of BAFF cytokine on mature B cells to treat autoimmune diseases.
Nguyen TG, et al. (2010) Anti-IgD antibody attenuates collagen-induced arthritis by selectively depleting mature B-cells and promoting immune tolerance. Journal of Autoimmunity; 35(1):86-97.
* The first study to demonstrate the novel therapeutic effects and mode of actions of anti-IgD mAb treatment in attenuating an autoimmune disease in an animal model of human rheumatoid arthritis.
Yenson VM, Nguyen TG, Ashton AW, Morris JM. Investigating the mechanisms of action of anti-IgD as the potential immune regulator. Journal of Reproductive Immunology (2010);86(1):51-53.
Warming J, Yenson VM, Nguyen TG, Peters L, Ashton AW, McCracken SA, Morris JM. Immunoglobulin D and the innate inflammatory response in preeclampsia. Journal of Reproductive Immunology (2010);86(1):64-65.
International Patents granted in Canada (2017), US (2016) US9156916B2, EU (2015), AU (2013). Title: “Modulation of T-helper cell-mediated Immune Response.” Inventors: Tue G. Nguyen, Jonathan M. Morris, Eileen G. Gallery, Sharon M. McCracken.
*****************************************
Independent Corroborating Studies
Amendt T, et al. Primary immune responses are controlled by IgD. Frontier Immunology (2021), 12:709240.
** This independent study confirms that the protective role of IgD and activated signals via IgD is required to ameliorate and moderate the disease severity in mouse model of autoimmune disease.
Ray A, et al. Mature IgD low/- B cells maintain tolerance by promoting regulatory T cell homeostasis. Nature Communication (2019);10(1):190-195.
** This independent study confirms that IgD low/negative B cells promote immune tolerance and recovery from EAE. These are the same B-cell populations that are selectively spared by anti-IgD antibody treatment, demonstrating the highly selective B cell depletions by anti-IgD treatment by removing the harmful mature B cells while sparing the beneficial regulatory B cell subsets as reported in this independent study and our previous publications (Nguyen TG et al., 2010; Nguyen TG, 2018).
Shan M, et al. Secreted IgD amplified humoral T helper 2 cell responses by binding basophils via gelactin-9 and CD44. Immunity (2018);137(5):1487-1497.
Kulkarni U, et al. IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration. Journal of Allergy & Clinical Immunology (2016);137(5):1487-1497.
** This independent study directly confirms and reproduces the in vivo therapeutic effects and biological activities of anti-IgD mAb treatment, which were previously reported in our published studies (Nguyen TG et al., 2010; Nguyen TG, 2018), in a different experimental animal model of autoimmune disease of epidermolysis bullosa acquisita.
Duong BH, et al. Peripheral B cell tolerance and function in transgenic mice expressing an IgD superantigen. Journal of Immunology (2010);184(8):4143-4158.
** This study used a transgenic mouse model that constitutively expressed the same anti-IgD antibody clone (AMS-9.1) used in all our studies and directly confirmed the key in vivo biological activities and effects of anti-IgD mAb treatment reported in our previous studies (Nguyen TG et al. 2010; Nguyen TG & Morris JM, 2014; Nguyen TG, 2018).
Zikherman J, Parameswaran R, Weiss A. Endogenous antigen tunes the responsiveness of naive B cell but not T cells. Nature (2012);489(7414):160-164.
** This independent study demonstrates that IgD(hi)IgM+ B-cell population is responsible for high production of harmful autoantibodies. This is the exact B-cell population that is specifically depleted by anti-IgD mAb treatment as reported by our previous study and others (Nguyen TG et al., 2010; Duong BH et al., 2010), demonstrating anti-IgD mAb treatment specifically deplete the right key B-cell population involved in autoimmunity.
Bruhl H, et al. B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating muring collagen-induced arthritis. European Journal of Immunology (2015);45(3):705-715.
Veri MC, et al. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis & Rheumatism (2010); 62(7):1933-1943.
** These independent studies demonstrates mAb treatment that targets membrane IgD signaling pathway via its membrane-anchor protein CD79b is effective and has superior efficacy to that of anti-CD20 mAb (Rituximab) in suppressing autoimmune arthritis in a mouse model, which has been reported in our recent study (Nguyen TG, 2018).
* A detailed seminar presentation of our scientific research data and corroborating evidence for investment due diligence and assessment is available upon a formal request. Please contact IMT directly for further information.
IgD Mab Technology (IMT) 